SARS-CoV Spike Glycoprotein Stable Cell Line

SARS-CoV Spike Glycoprotein Cell Line has been developed by stably transfecting HEK293T cell line with a SARS-CoV Spike Glycoprotein expression plasmid. This cell line provides consistent levels of expression of human SARS-CoV Spike Glycoprotein in cells surface. Each vial of cells contains more than 3 million viable cells stably expressing SARS-CoV Spike Glycoprotein with hygromycin resistance gene. SARS-CoV Spike Glycoprotein Cell line is ready to use in cell-based assay applications. This stably transfected clonal cell line provides consistent levels of expression, which helps simplify the interpretation of results. SARS-CoV Spike Glycoprotein HEK293T Cell line also allow to establish in vitro models for High Throughput and High Content Screening. Severe acute respiratory syndrome coronavirus (SARS-CoVs) infect human and animals and cause varieties of diseases, such as respiratory, enteric, renal, and neurological diseases. SARS-CoV uses its spike glycoprotein (S), a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry. It uses hACE2 to enter cells, correlating with the efficient spread of SARS-CoV among humans. S comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and also fusion of the viral and cellular membranes (S2 subunit). SARS-CoV Spike Glycoprotein Cell Line cell line allows the study of SARS-CoV spike/ACE2 interaction in cell-based assays.